What's Going on With Vera Therapeutics Stock on Tuesday?
Vera Therapeutics Phase 3 trial data show that Trutakna significantly reduces kidney disease progression in IgA nephropathy.
Stocks · News reference
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $125 to $90.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Vera Therapeutics shares are trading higher after the company announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy at risk for disease progression.
8-K filing — Vera Therapeutics, Inc. (VERA)
Filed: 2026-09-15 AccNo: 0001193125-26-391280 Size: 11 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Vera Therapeutics Announces TRUTAKNA Meets All Prespecified Endpoints Of Final Efficacy Analysis Of ORIGIN 3 Trial In Adults With Primary IgA Nephropathy At Risk For Disease Progression
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease